We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Agilent Technologies and Lipomics Collaborate

By Biotechdaily staff writers
Posted on 20 Feb 2007
Agilent Technologies Inc., (Santa Clara, CA, USA) and Lipomics Technologies Inc., (West Sacramento, CA, USA) will collaborate to develop diagnostic and research assays combining Agilent analytic platforms with Lipomics' expertise in biomarker discovery and validation.

The assays will focus on metabolic diseases, a family of related disorders driven in large part by subtle, long-term dysregulation of lipid metabolism. More...
Lipomics Technologies provides quantitative, diagnostically accurate measurements of more than 1,500 metabolites, allowing comprehensive profiling of whole-body lipid metabolism. The company's quantitative methods and expertise in lipid biology drive development of clinically relevant diagnostic and research assays. A wide range of Agilent liquid and gas chromatography, hyphenated technique instrumentation, reagents, microarrays, and informatics software will be deployed as needed.

Lipomics has developed considerable expertise in investigating the role that lipid metabolism plays in disease mechanisms, said Michael McNulty, general manager of Diagnostics, Agilent Life Sciences and Chemical Analysis. Both companies see significant synergies in combining this expertise with Agilent's capabilities to separate, detect, and analyze molecules in the development of new diagnostic tools.

We look forward to building clinically relevant diagnostic products together, said Meeta Patnaik, chief medical officer, Lipomics. Lipid diagnostics are [the] key to managing patients in areas such as cardiovascular risk, CNS disorders and inflammation, and requires the combination of well validated biomarkers and high-throughput technology for commercialization. The Agilent 2100 Bioanalyzer is [the] key to the collaboration, as the microfluidic-based lab-on-a-chip system delivers the analytic performance, automation, and low sample consumption required to study metabolic biomarkers.

Lipomics Technologies provides metabolic assessments for clinical diagnostics, personalized medicine, and drug research. The company's analytic technologies generate comprehensive, accurate, and quantitative profiles of lipid metabolites.

Agilent's bio-analytic measurement business provides application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify, and analyze the physical and biologic properties of substances and products.




Related Links:
Agilent
Lipomics

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Steam Sterilizer
Hi Vac II Line
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.